A Simple Automated Method for Detecting Recurrence in High-Grade Glioma

References

1. 1.↵
   2. Brandes AA

   . State-of-the-art treatment of high-grade brain tumors. Semin Oncol 2003;30:4–9 doi:10.1053/j.seminoncol.2003.11.028 pmid:14765377

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Hegi ME,
   3. Diserens A,
   4. Gorlia T, et al

   . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003 doi:10.1056/NEJMoa043331 pmid:15758010

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Stupp R,
   3. Hegt ME,
   4. Manson WP, et al

   ; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66 doi:10.1016/S1470-2045(09)70025-7 pmid:19269895

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Chan JL,
   3. Lee SW,
   4. Fraass BA, et al

   . Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002;20:1635–42 doi:10.1200/JCO.20.6.1635 pmid:11896114

   Abstract/FREE Full Text
5. 5.↵
   2. Barnard RO,
   3. Geddes JF

   . The incidence of multifocal cerebral gliomas: a histologic study of large hemisphere sections. Cancer 1987;60:1519–31 doi:10.1002/1097-0142(19871001)60:7<1519::AID-CNCR2820600719>3.0.CO%3B2-1 pmid:3113716

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Djalilian HR,
   3. Shah MV,
   4. Hall WA

   . Radiographic incidence of multicentric malignant gliomas. Surg Neurol 1999;51:554–57; discussion 557–58 doi:10.1016/S0090-3019(98)00054-8 pmid:10321888

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Jain R,
   3. Scarpace LM,
   4. Ellika S, et al

   . Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neurooncol 2010;96:423–31 doi:10.1007/s11060-009-9981-6 pmid:19859666

   CrossRefPubMed
8. 8.↵
   2. Schaff L,
   3. Donovan L,
   4. Lassman AB, et al

   . Imct-18pd-1 inhibitors for recurrent high grade glioma (Hgg). Neuro-Oncology 2015;17:v111.113–v111 doi:10.1093/neuonc/nov218.18

   CrossRef
9. 9.↵
   2. Telles BA,
   3. D'Amore F,
   4. Lerner A, et al

   . Imaging of the posttherapeutic brain. Top Magn Reson Imaging 2015;24:147–54 doi:10.1097/RMR.0000000000000051 pmid:26049818

   CrossRefPubMed
10. 10.↵
    2. Boxerman JL,
    3. Ellingson BM

    . Response assessment and magnetic resonance imaging issues for clinical trials involving high-grade gliomas. Top Magn Reson Imaging 2015;24:127–36 doi:10.1097/RMR.0000000000000054 pmid:26049816

    CrossRefPubMed
11. 11.↵
    2. Brandsma D,
    3. van den Bent MJ

    . Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 2009;22:633–38 doi:10.1097/WCO.0b013e328332363e pmid:19770760

    CrossRefPubMed
12. 12.↵
    2. Macdonald DR,
    3. Cascino TL,
    4. Schold SC Jr., et al

    . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–80 pmid:2358840

    Abstract
13. 13.↵
    2. Wen PY,
    3. Macdonald DR,
    4. Reardon DA, et al

    . Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 2010;28:1963–72 doi:10.1200/JCO.2009.26.3541 pmid:20231676

    Abstract/FREE Full Text
14. 14.↵
    2. Law M,
    3. Young RJ,
    4. Babb JS, et al

    . Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247:490–98 doi:10.1148/radiol.2472070898 pmid:18349315

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Lee J,
    3. Jain R,
    4. Khalil K, et al

    . Texture feature ratios from relative CBV maps of perfusion MRI are associated with patient survival in glioblastoma. AJNR Am J Neuroradiol 2016;37:37–43 doi:10.3174/ajnr.A4534 pmid:26471746

    Abstract/FREE Full Text
16. 16.↵
    2. Li Y,
    3. Lupo JM,
    4. Parvataneni R, et al

    . Survival analysis in patients with newly diagnosed glioblastoma using pre-and postradiotherapy MR spectroscopic imaging. Neuro Oncol 2013;15:607–17 doi:10.1093/neuonc/nos334 pmid:23393206

    Abstract/FREE Full Text
17. 17.↵
    2. Mardor Y,
    3. Pfeffer R,
    4. Spiegelmann R, et al

    . Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 2003;21:1094–100 doi:10.1200/JCO.2003.05.069 pmid:12637476

    Abstract/FREE Full Text
18. 18.↵
    2. Pyka T,
    3. Gempt J,
    4. Ringel F, et al

    . Prediction of glioma recurrence using dynamic 18F-fluoroethyltyrosine PET. AJNR Am J Neuroradiol 2014;35:1924–29 doi:10.3174/ajnr.A3980 pmid:24924547

    Abstract/FREE Full Text
19. 19.↵
    2. Jenkinson M,
    3. Beckmann CF,
    4. Behrens TE, et al

    . FSL. Neuroimage 2012;62:782–90 doi:10.1016/j.neuroimage.2011.09.015 pmid:21979382

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Klein A,
    3. Andersson J,
    4. Ardekani BA, et al

    . Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage 2009;46:786–802 doi:10.1016/j.neuroimage.2008.12.037 pmid:19195496

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Ellingson BM,
    3. Kim HJ,
    4. Woodworth DC, et al

    . Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 2014;271:200–10 doi:10.1148/radiol.13131305 pmid:24475840

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Lee VS,
    3. Flyer MA,
    4. Weinreb JC, et al

    . Image subtraction in gadolinium-enhanced MR imaging. AJNR Am J Neuroradiol 1996;167:1427–32 pmid:8956572

    PubMed
23. 23.↵
    2. Melhem ER,
    3. Mehta NR

    . Dynamic T1-weighted spin-echo MR imaging: the role of digital subtraction in the demonstration of enhancing brain lesions. J Magn Reson Imaging 1999;9:503–08 doi:10.1002/(SICI)1522-2586(199904)9:4<503::AID-JMRI1>3.0.CO%3B2-0 pmid:10232507

    CrossRefPubMed
24. 24.↵
    2. Prager AJ,
    3. Martinez N,
    4. Beal K, et al

    . Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol 2015;36:877–85 doi:10.3174/ajnr.A4218 pmid:25593202

    Abstract/FREE Full Text
25. 25.↵
    2. Cha J,
    3. Kim ST,
    4. Kim HJ, et al

    . Analysis of the layering pattern of the apparent diffusion coefficient (ADC) for differentiation of radiation necrosis from tumour progression. Eur Radiol 2013;23:879–86 doi:10.1007/s00330-012-2638-4 pmid:22903642

    CrossRefPubMed